Use of Low Molecular Weight Heparin in Pregnancy

Summary

In a controlled study of 15 pregnant patients undergoing therapeutic termination of pregnancy, seven received subcutaneously 5,000 anti-FXa units of low molecular weight (LMW) heparin 15 and 3 h prior to the termination, and eight patients acted as controls. Paired maternal and fetal blood samples were taken (before or immediately after the termination) for assay of heparin activity by a chromogenic anti-FXa method sensitive to levels of 0.02 anti-FXa U/ml. LMW heparin was detected in all maternal samples of the test patients but was not detected in any of the fetal samples.

The use of LMW heparin as a thromboprophylactic agent was then evaluated in 11 patients who were known to have a severe thromboembolic tendency, had suffered recurrent miscarriages and had responded poorly to conventional anticoagulation (oral anticoagulant, conventional heparin). All patients receiving LMW heparin in thromboprophylactic doses completed uneventful pregnancies and gave birth to healthy babies (three for the first time) without complication. Bone density scans performed in all patients shortly after the delivery showed normal mineral mass. We conclude that LMW heparin does not cross the placental barrier, and in addition offers satisfactory antithrombotic protection for both maternal and placental circulation. In addition, this study provides preliminary data from 11 patients suggesting LMWH may not give rise to maternal osteoporosis, a finding that now needs further investigation.

• REFERENCES

• 1 Bonnar J. Haemostasis and coagulation disorders in pregnancy. In: Haemostasis and Thrombosis. Bloom AL, Thomas DP. (eds) Churchill: London: 1987. 34 570-584
• 2 Royal College of General Practitioners Oral contraception and thromboembolic disease. J Coll Gen Pract 1967; 13: 267-279
• 3 Badaracco MA, Vessey M. Recurrence of venous thromboembolism disease and use of oral contraceptives. Br Med J 1974; 2: 215-217
• 4 Wilcox AJ, Weinberg CR, O’Connor JF, Baird DD, Schlatterer JP, Canfield RE, Armstrong EG, Nisula BC. Incidence of early loss of pregnancy. N Engl J Med 1988; 319: 189-194
• 5 Hall RG, Pauli RM, Wilson KM. Maternal and fetal sequelae of anticoagulation during pregnancy. Am J Med 1980; 68: 122-140
• 6 Flessa HC, Kopstrom AB, Glueck HI, Will JJ. Placental transport of heparin. Am J Obstet Gynecol 1965; 93: 570-573
• 7 Kapch D, Silver D. Heparin-induced thrombocytopenia, thrombosis and haemorrhage. Arch Surg 1981; 116: 1423-1429
• 8 Ginsberg JS, Hirsh J. Anticoagulants during pregnancy. Annu Rev Med 1989; 40: 79-86
• 9 Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, Webber C. Heparin effect on bone density. Thromb Haemostas 1990; 64: 286-289
• 10 Bergqvist D, Hedner U, Sjorin E, Holmer E. Anticoagulant effects of two types of low molecular weight heparin administered subcutaneously. Thromb Res 1983; 32: 381-391
• 11 Johnson A, Kirkwood TBI, Stirling Y, Perez-Requejo JI, Ingram GIC, Bangham DR, Brozovic M. Four heparin preparations: Anti-Xa potentiating effect of heparin after subcutaneous injection. Thromb Haemostas 1976; 35: 586-591
• 12 Murray WJG. Low molecular weight heparin in surgical practice. MS Thesis 1985; 4: 124-149
• 13 Melissari E, Parker CJ, Kakkar VV. Use of low molecular weight heparin in pregnancy. Thromb Haemostas 1989; 62: 451
• 14 Bang J. Ultrasound-guided fetal blood sampling. In: Progress in Perinatal Medicine. Albertini A, Crosignani PG. (eds) Excerpta Medica: Amsterdam: 1983. pp 223-225
• 15 Melissari E, Scully MF, Paes T, Kakkar VV. The influence of LMW heparin on the coagulation and fibrinolytic response to surgery. Thromb Res 1985; 37: 115-126
• 16 Melissari E, Nicolaides KH, Scully MF, Kakkar VV. Protein S and C4b-binding protein in fetal and neonatal blood. Br J Haematol 1988; 70: 199-203
• 17 Blombäck B, Blombäck M. Purification of human and bovine fibrinogen. Arkiv Kemi 1956; 10: 415-417
• 18 Thiagarajan P, Pengo V, Shapiro SS. The use of dilute Russell’s viper venom for the diagnosis of lupus anticoagulants. Blood 1986; 68: 859-864
• 19 Lane DA, McGregor IR, Michalski R, Kakkar VV. Anticoagulant activities of four unfractionated and fractionated heparins. Thromb Res 1978; 12: 257-271
• 20 Carter CJ, Kelton JG, Hirsh J, Cersksus A, Santos AV, Gent M. The relationship between the haemorrhagic and antithrombotic properties of low molecular weight heparin in rabbits. Blood 1982; 59: 1239-1245
• 21 Nicolaides KH, Rodeck CH, Mibashan RS. Obstetric and diagnosis of haematological disease in the fetus. Clin Haematol 1985; 14: 775-805
• 22 Forestier F, Daffos F, Capell-Pavlovsky M. Low molecular weight heparin (PK 10169) does not cross the placenta during the second trimester of pregnancy. Study by direct fetal blood sampling under ultrasound. Thromb Res 1984; 34: 557-560
• 23 Omri A, Delaloye JF, Andersen H, Bachmann F. Low molecular weight heparin novo (LHN-1). Does not cross the placenta during the second trimester of pregnancy. Thromb Haemostas 1989; 61: 55-56
• 24 Forestier F, Daffos F, Rainaut M, Toulemonde F. Low molecular weight heparin (CY 216) does not cross the placenta during the third trimester of pregnancy. Thromb Haemostas 1987; 57: 234 (Letter)
• 25 Andrew M, Boneu B, Cade J, Cerskus AL, Hirsh J, Jeffries A, Towell ME, Buchanan MR. Placental transport of low molecular weight heparin in the pregnant sheep. Br J Haematol 1985; 59: 103-108
• 26 Dansis J. Neonatology, pathophysiology and Management of the Newborn. Avery GB. (ed) 2nd edn. Lippincott: Philadelphia, PA: 1981. pp 099-106
• 27 Priollet P, Roncaato M, Aiach M, Housset E, Poissonier MH, Chavinie J. Low molecular weight heparin in venous thrombosis during pregnancy. Br J Haematol 1986; 63: 605-606
• 28 De Boer K, Heyboer H, ten Cate JW, Borm JJJ, van Ginkel CJW. Low molecular weight heparin treatment in a pregnant woman with allergy to standard heparins and heparinoid. Thromb Haemostas 1989; 61: 148 (Letter)
• 29 Lubbe WF, Butler WS, Palmer SJ, Liggins GC. Fetal survival after prednisone suppression of maternal lujpus anticoagulant. Lancet 1983; i: 1361-1363
• 30 Hughes GRV. Systemic lupus erythematosus. Lacjmann PJ, Peters DK. Blackwell Scientific Publications, Clin Aspects Immunol: 1977. 2 1196-1216
• 31 Department of Health Late deaths. In: Report on Confidential Enquiries into Maternal Deaths in England and Wales 1982–1984. 1989. 16 121-125
• 32 Dun WL, Wahner HW, Riggs BL. Measurements of bone mineral content in human vertebrae and hip by dual photon absorptiometry. Radiology 1980; 136: 485-487
• 33 Riggs BL, Wahner HW. Bone densitometry and clinical decision making in osteoporosis. Ann Intern Med 1988; 108: 293-295
• 34 Riggs BL, Melton LJ. Involutional osteoporosis. N Engl J Med 1986; 314: 1676-1686